

The Philadelphia Department of Public Health (PDPH) and the Centers for Disease Control and Prevention (CDC) recommend that:

This patient should immediately be placed on **contact precautions**

This patient has been colonized or infected with *Candida auris*. *Candida auris* is a difficult to detect yeast that can cause life-threatening infections and has caused long-lasting outbreaks in healthcare facilities (HCFs). It is easily spread, hard to remove from the environment, and often very resistant to antifungal medications. Implementation of Transmission-Based Precautions is necessary to prevent outbreaks. Contact Precautions should be implemented by all HCFs, including long-term care facilities (LTCFs), as the primary option. LTCFs may be able to utilize Enhanced Barrier Precautions* for long-term management of these patients per CDC guidance and in consultation with the PDPH.

Contact Precautions and Recommendation Checklist:

- This patient should be placed in a private room, if possible.**
- Healthcare personnel interacting with patients on Contact Precautions, or their environment, are required
 to wear a gown and gloves, donning their PPE upon room entry and properly discarding before exiting
- Healthcare personnel should conduct diligent hand hygiene during and after contact with a *C. auris*patient or their environment; Ensure alcohol-based hand rub is readily available
- Disposable or dedicated patient-care equipment should be used whenever possible
- All disinfection should be completed with an Environmental Protection Agency (EPA) registered disinfectant effective against Candida auris or Clostridium difficile. Cleaning and disinfection should be performed according to the manufacturer's instructions for use. Examples include:
 - Shared equipment should be thoroughly cleaned/disinfected after contact with this patient (e.g. stethoscopes, X-ray machines, respiratory therapy equipment)
 - The patient's room should be cleaned/disinfected daily and terminally upon discharge
 - O Transport vehicles/equipment should be terminally cleaned/disinfected after use
- Ensure written and verbal communication of isolation status for intra and inter-facility transfers
- * More information on Enhanced Barrier Precautions can be found on CDC's website: https://www.cdc.gov/long-term-care-facilities/hcp/prevent-mdro/ppe.html Enhanced barrier precautions should only be used in the place of contact precautions under consultation with PDPH.
- ** If a patient cannot be placed in a private room, ensure roommates are at low risk of developing *Candida* infections (e.g., no immunocompromising conditions, antifungal therapies, indwelling devices or open wounds), maintain separation of at least 3 feet, use privacy curtains to limit direct contact, clean/disinfect surfaces on a more frequent schedule, and have healthcare workers change PPE and perform hand hygiene when moving between roommates. Patients with *C. auris* who have uncontained secretions, excretions, acute diarrhea, or draining wounds should only be roomed with other *C. auris* patients



This patient was identified to have Candida auris: (select one) Infection					tient Name/ID:
This patient was identified to have Candida auris: (select one) Infection					ompleting facility:
☐ This infection has been treated (patient is likely to be colonized an maintained on contact precautions) ☐ Treatment is ongoing ☐ Colonization This case status is: (select one) ☐ Confirmed: Candida auris was isolated from a body site ☐ Under investigation: Laboratory results are pending and Candida auris is The organism was isolated from the patient's: (check all that apply) ☐ Skin ☐ Blood ☐ Urine ☐ Respiratory tract ☐ Wound ☐ Stool ☐ Other: The Isolation/Transmission-based Precaution status at time of discharge: ☐ Contact ☐ Droplet ☐ Airborne ☐ Enhanced barrier Other organisms requiring isolation:					
maintained on contact precautions) Treatment is ongoing Colonization This case status is: (select one) Confirmed: Candida auris was isolated from a body site Under investigation: Laboratory results are pending and Candida auris is The organism was isolated from the patient's: (check all that apply) Skin Blood Urine Respiratory tract Wound Stool Other: The Isolation/Transmission-based Precaution status at time of discharge: Contact Droplet Airborne Enhanced barrier Other organisms requiring isolation: Most recent topical antiseptic application (chlorhexidine gluconate [CHG]) if applicable Date: Body Sites:				on	○ Infectio
Colonization This case status is: (select one)	nd should be	-			
This case status is: (select one) Confirmed: Candida auris was isolated from a body site Under investigation: Laboratory results are pending and Candida auris is The organism was isolated from the patient's: (check all that apply) Skin Blood Urine Respiratory tract Wound Stool Other: The Isolation/Transmission-based Precaution status at time of discharge: Contact Droplet Airborne Enhanced barrier Other organisms requiring isolation: Most recent topical antiseptic application (chlorhexidine gluconate [CHG]) if applicable Date: Body Sites:			ngoing	Treatment is or	
Confirmed: Candida auris was isolated from a body site				ation	○ Coloniz
Skin Blood Urine Respiratory tract Wound Stool Other: The Isolation/Transmission-based Precaution status at time of discharge: Contact Droplet Airborne Enhanced barrier Other organisms requiring isolation: Most recent topical antiseptic application (chlorhexidine gluconate [CHG]) if applicable Date: Body Sites:	suspected	•		ned: Candida at	○ Confirm
□ Wound □ Stool □ Other: The Isolation/Transmission-based Precaution status at time of discharge: □ Contact □ Droplet □ Airborne □ Enhanced barrier Other organisms requiring isolation: □ Most recent topical antiseptic application (chlorhexidine gluconate [CHG]) if applicable Date: □ Body Sites:		(check all that apply)	he patient's: (ch	solated from th	The organism was is
The Isolation/Transmission-based Precaution status at time of discharge: Contact Droplet Airborne Enhanced barrier Other organisms requiring isolation: Most recent topical antiseptic application (chlorhexidine gluconate [CHG]) if applicable Date: Body Sites:		☐ Respiratory tract	☐ Urine	\square Blood	☐ Skin
Contact Droplet Airborne Enhanced barrier Other organisms requiring isolation: Most recent topical antiseptic application (chlorhexidine gluconate [CHG]) if applicable Date: Body Sites:			\square Other:	☐ Stool	☐ Wound
Other organisms requiring isolation: Most recent topical antiseptic application (chlorhexidine gluconate [CHG]) if applicable Date: Body Sites:		atus at time of discharge:	recaution statu	nission-based P	The Isolation/Transm
Most recent topical antiseptic application (chlorhexidine gluconate [CHG]) if applicable Date: Body Sites:		e 🗆 Enhanced barrier	☐ Airborne	\square Droplet	☐ Contact
Date: Body Sites:			1:	uiring isolation	Other organisms requ
	le:	hexidine gluconate [CHG]) if applicable:	ication (chlorhe	antiseptic appli	Most recent topical a
Additional Notes:				ly Sites:	Date: Bod
					Additional Notes:

Resources

PDPH Health Information Portal for *Candida auris*: https://hip.phila.gov/disease-control/diseasesconditions/candida-auris/ Infection Prevention and Control for *Candida auris*: https://www.cdc.gov/candida-auris/hcp/infection-control/ Inter-facility IC Transfer Form: https://www.cdc.gov/healthcare-associated-infections/media/pdfs/Interfacility-IC-Transfer-Form-508.pdf